Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.56 |
| ▸ | CTSL | P07711 | 7/20 | 0.42 |
| ▸ | CTSB | P07858 | 7/20 | 0.42 |
| ▸ | CTSK | P43235 | 7/20 | 0.42 |
| ▸ | CTSS | P25774 | 2/20 | 0.42 |
| ▸ | CTSC | P53634 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 12/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1103885 | 0.79 | GPR119 (0.48) | GPR119CTSLCTSBCTSKCTSS | |
| SCHEMBL6125659 | 0.78 | GPR119 (0.52) | GPR119CTSLCTSBCTSKCTSS | |
| SCHEMBL27870578 | 0.78 | GPR119 (0.52) | GPR119CTSLCTSBCTSKCTSS | |
| SCHEMBL1307330 | 0.76 | ALOX5 (0.38) | GPR119 | |
| SCHEMBL13180108 | 0.76 | GPR119 (0.50) | GPR119CTSLCTSBCTSKCTSS | |
| SCHEMBL27870587 | 0.74 | GPR119 (0.48) | GPR119CTSLCTSBCTSKCTSS | |
| SCHEMBL28228366 | 0.74 | CTSK (0.51) | GPR119CTSLCTSBCTSKCTSS | |
| SCHEMBL4375132 | 0.73 | MAOB (0.34) | — | |
| SCHEMBL15047082 | 0.72 | — | — | |
| SCHEMBL368612 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3440087-B1 | THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS | MANKIND PHARMA LTD (IN) | 2022-08-10 | — | — | EP | disclosed |
| CN-109415381-B | Thiazolopyridine derivatives as GPR119 agonists | 人类制药有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-10919915-B2 | Compounds as GPR119 agonists | MANKIND PHARMA LTD. (IN) | 2021-02-16 | — | — | US | disclosed |
| US-10919915-B2 | Compounds as GPR119 agonists | MANKIND PHARMA LTD. (IN) | 2021-02-16 | — | — | US | disclosed |
| US-20200040006-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2020-02-06 | — | — | US | disclosed |
| US-20200040006-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2020-02-06 | — | — | US | disclosed |
| CN-109415381-A | Thiazolopyridine derivatives as GPR119 agonist | 人类制药有限公司 | 2019-03-01 | — | — | CN | disclosed |
| EP-3440087-A1 | THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS | MANKIND PHARMA LTD (IN) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017175068-A1 | THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017175068-A1 | THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | WO | disclosed |
| CN-101657471-A | Bicyclic compounds and their use as antidiabetics | SMITHKLINE BEECHAM CORP US | 2010-02-24 | — | — | CN | disclosed |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITH KLINE BEECHAM CORPORATION a corporation | 2010-02-04 | — | — | US | disclosed |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITH KLINE BEECHAM CORPORATION a corporation | 2010-02-04 | — | — | US | disclosed |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITH KLINE BEECHAM CORPORATION a corporation | 2010-02-04 | — | — | US | disclosed |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-10-29 | — | — | US | disclosed |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-10-29 | — | — | US | disclosed |
| EP-2094683-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SmithKline Beecham Corporation (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2009038974-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-03-26 | — | — | WO | disclosed |
| WO-2008070692-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008070692-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200040006-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | GPR119, GPR84, GPR65 | GPR119 1/4885CTSL 3546/4885CTSB 2135/4885 |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | GPR119 1/4885CTSL 2865/4885CTSB 941/4885 |
| US-10919915-B2 | Compounds as GPR119 agonists | GPR119, GPR84, GPR65 | GPR119 1/4885CTSL 3748/4885CTSB 2220/4885 |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | GPR119 1/4885CTSL 3181/4885CTSB 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.